Learn more at bit.ly/roguetherapeutics
Now that we have had our first scientific successes in precision medicine and even a new federal precision medicine initiative, will it help us treat disease? Even if we can more precisely diagnose patients and prognosticate about their future, does this mean we will have the right treatments for them? Do we have to wait for the traditional flow of science through the large pharmaceutical companies to get new effective drugs? Will engineering, whether in gene editing or device hacking, revolutionize care?
Precision Medicine: Rogue Therapeutics will directly address these questions and give a premeditatedly iconoclastic perspective. Our keynote speaker, Karen Aiach, did not start in medicine or pharmaceuticals, but specifically because of her long clinical journey with her daughter has founded a rapidly-growing biotech company for the treatment of the disorders of her child and those of others. We will also have panels featuring similarly patient-focused and even impatient approaches to finding therapies. As you can see from the agenda, this symposium follows very much in the spirit of our successful conference last year, Precision Medicine: Patient Driven.
AGENDA
– Welcome and Opening Remarks – Zak Kohane
– Keynote – “Rare Informs the Common” – Karen Aiach, Lysogene
PANEL 1: What is driving Precision Medicine?
– Ashish Jha, Harvard School of Public Health (moderator)
– Carey Goldberg, WBUR
– Gail Marcus, ELI Healthcare Consultant
– Joseph Newhouse, Health Care Policy, Harvard Medical School
PANEL 2: What happens when patients take over?
– Bill Gahl, Undiagnosed Diseases Network (moderator)
– Matt Might, University of Utah
– Eric Minikel & Sonia Vallabh, Broad Institute
– Alison Skrinar, UltraGenyx Pharmaceutical
PANEL 3: Marijuana: recreational to medicinal?
– Donald Abrams, University of California San Francisco
– Wayne Hall, University of Queensland
– Ryan Vandrey, Johns Hopkins University
– Larry Wolk, Colorado State Public Health
PANEL 4: Will engineering disrupt therapeutics?
– Daniel Anderson, Harvard-MIT Biomedical Engineering Center
– George Church, Harvard Medical School
– Ed Damiano, Boston University
– Alison Marsden, Stanford University
Conference co-sponsored by DBMI and PIC-SURE, a BD2K Center of Excellence
Likes: 1
Viewed: 1208
source